Stage 0

1:32

Dr. Rick Baehner talks about DCIS and invasive breast cancer and how the Oncotype DX DCIS Test Score identifies the aggressiveness of the cancer tumor tissue and the level of risk for the patient.

5:50

I was diagnosed with Invasive Ductal Carcinoma, Stage IIA 3+ lymph nodes-Estrogen+/Her2- on June 1, 2012 at 31 years old. I discovered my tumor on my own once I stopped breast feeding my second daughter. She was only 8 months old at the time :( This past year has been tough but LIFE CHANGING to say the least! The love of my family & my two girls keep me smiling! I have nothing but respect for ALL who have been touched by Cancer! Love & Light xo

1:12

Genomic Health's Senior Director of Pathology, Dr. Rick Baehner, describes how the Oncotype DX DCIS Score is revolutionizing the way that DCIS breast cancer is being treated. Pathologists no longer have to rely on subjective assessments and can now examine individual breast cancer tumors to determine the aggressiveness.

5:09

In this video, Dr. Harness explains the reoccurrence rate for patients who are newly diagnosed with DCIS. Click Here & Get The 15 Breast Cancer Questions To Ask Your Doctor http://www.breastcanceranswers.com/what-breast-cancer-questions-to-ask/#
 
Breast Cancer Answers is a social media show where viewers submit a question and get the answer from an expert. Submit your question now at, http://www.breastcanceranswers.com/ask.
 
This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk. If you have any concerns about your health, please consult with a physician.

0:57

The Oncotype DX DCIS Score is determined by examining a piece of breast cancer tumor tissue obtained at the time of surgery. Genomic Health's Senior Director of Pathology, Dr. Rick Baehner, talks about how the test measures the levels of tumor-associated genes.

0:50

Patients diagnosed with DCIS breast cancer should talk to their surgeon or radiation oncologist about ordering the Oncotype DX DCIS Breast Cancer Assay so they can get a DCIS Score and determine the best treatment plan, according to Genomic Health's Senior Director of Pathology, Dr. Rick Baehner.

1:15

Dr. Rick Baehner, Senior Director of Pathology at Genomic Health, recounts a recent experience he had with a DCIS breast cancer patient.

1:32

Genomic Health Senior Director of Pathology Dr. Rick Baehner examines the benefits using the Oncotype DX DCIS Score over other tools that are currently being used to create DCIS breast cancer treatment decisions.

Advertisement